Current stock page

Financial Data

OGN Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareDrug Manufacturers - GeneralScore data as of Sep 4, 2026

OGN

Financial Data
Organon & Co.
Healthcare· Drug Manufacturers - General
AIQ Score
NeutralAIQ Edge 10/10
Leader
Sector Leader
Score data as of Sep 4, 2026
Last price
$13.78
+$0.01 (+0.07%)
Latest market quote
Momentum78
Value75
Quality47
Risk Resilience70
Sentiment
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 6, 2026.

Income statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Revenue$1.56B$1.46B$1.51B$1.6B$1.59B$1.51B$1.59B$1.58B
Gross Profit$847M$783M$759M$857M$874M$841M$896M$923M
Operating Income
Net Income$108M$146M-$205M$160M$145M$87M$109M$359M
EPS$0.41$0.55-$0.79$0.62$0.56$0.34$0.42$1.39
Cash flow statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Operating Cash Flow$107M$225M$0$264M$220M$75M$390M$141M
Capital Expenditure-$42M-$37M$0-$115M-$39M-$97M-$132M-$76M
Free Cash Flow$65M$188M$0$149M$181M-$22M$258M$65M
Net Cash Provided By Operating Activities$107M$225M$0$264M$220M$75M$390M$141M
Balance sheet
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Assets$13.18B$13B$0$13.55B$13.5B$13.16B$13.1B$12.75B
Total Debt$8.55B$8.57B$0$8.83B$8.9B$8.96B$9.04B$8.75B
Cash And Cash Equivalents
Total Liabilities$12.17B$12.09B-$906M$12.65B$12.77B$12.61B$12.63B$12.26B
Total Stockholders Equity$1.01B$903M$906M$906M$733M$542M$472M$493M
Key financial metrics
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio8.262.72-2.274.344.3411.038.823.43
P/B ratio3.531.732.063.063.437.088.159.99
P/S ratio2.281.071.241.731.582.542.423.11
Debt To Equity8.59.4909.7412.1416.5219.1417.75
Free Cash Flow Yield
Financial ratios
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
P/E ratio
P/B ratio3.531.732.063.063.437.088.159.99
P/S ratio2.281.071.241.731.582.542.423.11
Return On Equity10.74%16.17%-22.63%17.66%19.78%16.05%23.09%72.82%
Debt To Equity

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
17.42
multipleSep 4, 2026
Pb
3.59
multipleSep 4, 2026
Revenue Growth Yoy
6.71
percentSep 4, 2026
EPS Growth Yoy
-25.45
percentSep 4, 2026
Gross Margin
52.98
percentSep 4, 2026
Operating Margin
19.29
percentSep 4, 2026
ROE
23.44
percentSep 4, 2026
ROIC
4.73
percentSep 4, 2026
Debt To Equity
8.5
ratioSep 4, 2026
FCF Yield
13.78
percentSep 4, 2026
Technical indicators
Close
13.78
priceSep 4, 2026
Volume
4,872,489
volumeSep 4, 2026
Rsi14
78.57
indexSep 4, 2026
MACD
0.06
indexSep 4, 2026
MACD Signal
0.06
indexSep 4, 2026
MACD Histogram
-0.01
indexSep 4, 2026
Adx14
50.79
indexSep 4, 2026
Sma50
13.61
priceSep 4, 2026
Sma200
10.28
priceSep 4, 2026
Atr14
0.04
priceSep 4, 2026
Historical Volatility
0.03
percentSep 4, 2026
Volume Ma20
3,283,435.7
volumeSep 4, 2026
Risk measures
Resilience Score
70
score_0_100Sep 4, 2026
Beta
1.52
ratioSep 4, 2026
Volatility Annual
68.01
percentSep 4, 2026
Max Drawdown
-48.23
percentSep 4, 2026
Sharpe Ratio
0.79
ratioSep 4, 2026
Var95
-4.01
percentSep 4, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

OGN Financial Data FAQ

What is Organon & Co.'s revenue?

Organon & Co.'s revenue is one of the core financial data points for OGN. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Organon & Co.'s revenue growing?

Revenue growth shows whether Organon & Co. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is OGN's EPS?

OGN's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Organon & Co.'s net income?

Organon & Co.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Organon & Co. generate?

Free cash flow shows how much cash Organon & Co. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Organon & Co. have?

Cash and debt help frame OGN's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.